openPR Logo
Press release

Reliable Coronavirus (COVID-19) antibody testing - the two biotechnology companies CANDOR Bioscience GmbH and trenzyme GmbH make with their products an important contribution to COVID-19 test development

06-26-2020 05:07 PM CET | Science & Education

Press release from: trenzyme GmbH

Pipetting of an ELISA plate Copyright CANDOR Bioscience GmbH

Pipetting of an ELISA plate Copyright CANDOR Bioscience GmbH

In dealing with the COVID 19 pandemic, a reliable SARS-CoV-2 antibody test is urgently needed worldwide to determine whether a person has already been infected with the virus. Many of the currently available tests are not yet optimally developed and can lead to false positive results. However, for mass testing of the population an extremely high specificity, i.e. a low rate of false-positive results, is absolutely essential. To achieve this specificity, high-quality components and reliable immunological test methods are required. The two biotechnology companies CANDOR Bioscience and trenzyme make a major contribution to this with their products and offer highly specific components for more significant antibody tests against SARS-CoV-2.

Various studies show that the RBD (Receptor Binding Domain) of the SARS-CoV-2 spike protein could be a very promising antigen for highly specific antibody tests. The German biotechnology company trenzyme, based in Konstanz, produces this important surface protein of SARS-CoV-2 in a very high quality and on a large scale to supply researchers from all over the world who are working on different test methods or on the development of COVID-19 drugs.

CANDOR Bioscience, based in Wangen (Germany), also uses the protein produced by trenzyme for the development of their assays: "We use the SARS-CoV-2 RBD protein in the development of ELISAs. In contrast to other possible antigens, the RBD antigen supplied by trenzyme has proven to be highly specific for the recognition of patient antibodies. However, in long-term storage such antigens can be unstable and lose their function. The shelf life of the RBD protein in ELISA kits is less than 2 weeks. With our Stabilizer we can stabilize the protein so good that the production of stable and reliable diagnostics is possible without any problems. Due to the ideal combination of trenzyme’s produced protein and our products, we are enabling the development of fast and reliable SARS-CoV-2 IgG antibody testing," said Dr. Peter Rauch, co-founder and CEO of CANDOR.

For the global, high-volume use of a commercial test in a pandemic, the stability of the reagents and the associated kit shelf life play a crucial role. By using stabilizers, such as in this case the Coating Stabilizer Liquid Plate Sealer® from CANDOR, immunodiagnostic components in the kit remain stable and fully functional even after prolonged storage (usually 2-3 years).

In addition to the choice of a high specific capture protein - in this case the RBD of SARS-CoV-2 spike protein – and the stability of the reagents, there are also other important aspects to be considered to avoid false positive results in antibody testing. Cross-reactivities, biochemical interference and nonspecific binding should be avoided. They trigger a signal in the immunoassay and thus lead to a false result. To prevent this issues CANDOR offers specific solutions which effectively combat the causes and make the assays reliable.

The described challenges show how complex the development of reliable immunodiagnostics for COVID-19 is and that cooperations such as the one between trenzyme and CANDOR Bioscience are very effective and important in overcoming the current crisis. "We are pleased to support CANDOR in the optimisation of their ELISAs with our produced proteins and to be able to increase the reliability of antibody-based tests through our cooperation and thus make our contribution to the fight against coronavirus," said Dr. Reinhold Horlacher, founder and CEO of trenzyme.

trenzyme GmbH
Lena Mast
Online Marketing Manager
Byk-Gulden-Str. 2
78467 Konstanz
Email: lena.mast@trenzyme.com
Phone: +49 7531 12290 0
Web: www.trenzyme.com

CANDOR BioScience GmbH
Dr. Sabine Glöggler
Head of Marketing
Simoniusstr. 39
88239 Wangen
Email: s.gloeggler@candor-bioscience.de
Phone: +49 7522 79 52 70
Web: www.candor-bioscience.de

About trenzyme GmbH:
trenzyme GmbH was founded in 2000 as a spin-off of the Microbiological Institute of the University of Constance and has been operating for 20 years as a research service provider in the fields of cell line development and recombinant protein production. As an outsourcing partner, the company provides tailor-made services to support the research and development departments of academic institutes, biotechnology companies and pharmaceutical companies from all over the world.

About CANDOR Bioscience GmbH:
CANDOR is an internationally active company that develops, produces and markets high-quality solutions for immunoassays. The product range comprises more than 50 different products, including stabilizers, HAMA and interference blockers, surface blockers and other high-quality buffer solutions, which are sold to immunodiagnostics manufacturers, research-based pharmaceutical companies and research institutes worldwide. The use of these solutions can improve the reliability of results, simplify test procedures and reduce processing time. All CANDOR products are manufactured with the highest possible quality standards in Wangen im Allgäu (Made in Germany).

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Reliable Coronavirus (COVID-19) antibody testing - the two biotechnology companies CANDOR Bioscience GmbH and trenzyme GmbH make with their products an important contribution to COVID-19 test development here

News-ID: 2080683 • Views: 323

More Releases from trenzyme GmbH

trenzyme GmbH offers recombinant SARS-CoV-2 S1 protein to support Coronavirus re …
The 2019 novel coronavirus SARS-CoV-2 has caused an outbreak of the respiratory illness COVID-19 that started in China and has now spread throughout the world. Meanwhile, the spread of coronavirus has a strong impact on our daily life and the World Health Organization (WHO) has declared a global health emergency to gather resources to fight against this threat. To support SARS-CoV-2 research, trenzyme offers off-the-shelf recombinant protein of the receptor

More Releases for CANDOR

Global Radiotherapy Patient Positioning Accessories Market 2019 Analysis with Ke …
In terms of regions, North America and Europe are expected to remain the largest market for radiotherapy patient positioning accessories during the forecast period. According to this study, over the next five years the Radiotherapy Patient Positioning Accessories market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents
Global Aluminium Clad Printed Circuit Board Market Projections Deliver Positive …
An aluminium clad printed circuit board is a thermally-conductive printed circuit board that provides enhanced heat dissipation without demanding an external heat sink. This property widely impacts the performance of the circuit board as it reduces the thermal stress on the attached components. Aluminium Clad Printed Circuit Board Market witness relatively high demand among all MCPCBs (Metal Clad Printed Circuit Boards), owing to their relatively low cost. They are also
Compound Clotrimazole Ointment Market 2017-2022 Merck & Co. Inc., GlaxoSmithKlin …
Global Compound Clotrimazole Ointment Market Size, Status and Forecast 2022 provides Market information about Manufacturers, Countries, Type and Application.This Industry report also states Company Profile, sales, Compound Clotrimazole Ointment Market revenue and price, market share, market growth and gross margin by regions. Top Manufacturers/Key Players: Merck & Co. Inc. GlaxoSmithKline Plc. Alves Health Care Pvt. Ltd. Aidance Skincare & Topical Solutions, LLC Capital Pharmaceutical Shanghai Songhua Pharmaceutical Co., Ltd. Karnataka Antibiotics & Pharmaceuticals Limited (KAPL) Candor Biotech Ltd. Helax
Sri Lanka Mutual Fund Sector Sri Lanka Mutual Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents What are Unit Trusts (Mutual Fund)? Types of Unit Trusts (Mutual Funds) in Sri Lanka 2.1 Types of Funds 2.1.1 Open Ended Funds 2.1.2 Closed Ended Funds 2.2 Types of Trust Units 2.2.1 Gilt Edged Funds 2.2.2 Indexed Funds 2.2.3 Income Funds or High Yield Funds
THE LOBBY touted a "must read"
Winner of the National Indie Excellence Award for General Fiction, the 2016 Beach Book Festival, 2016 Amsterdam Book Festival, Runner up in the 2016 Paris and Los Angeles Book Festival and more – The Lobby has been touted as a “must read” this summer. “A highly entertaining and original novel you will absolutely love, don't hesitate to add The Lobby to your list of 'must reads' for the weeks
ReadyTector®, CANDOR’s all-in-one Solution for Western Blotting
CANDOR launches its newly developed all-in-one Solution for Western blotting at the industrial fair analytica. The innovative ReadyTector® Solution allows a quick one-step immunodetection. ReadyTector® provides sharp bands and less background for standard Western blotting applications. ReadyTector® enables a significant time saving in Western blot analysis. CANDOR expands its broad selection of premium solutions for immunoassays with ReadyTector®, the all-in-one Solution for Western blotting. With ReadyTector® the originator of LowCross-Buffer® expands